Xenetic Biosciences, Inc.

menu

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Technology
    • Overview
    • DNase Platform
    • XCART™ Platform
    • PolyXen®
    • Publications
  • Product Pipeline
    • Overview
    • DNase
    • XCART™
    • PolyXen®
  • News & Media
    • Press Releases
    • Presentations
    • Multimedia
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Information
    • Financials
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Proxy Materials
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

All SEC Filings

Filter Filings:
Date Form Description Docs XBRL Pages
11/09/22 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
HTML PDF XBRL Viewer XLS XBRL Files 19
10/21/22 SC 13G Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions HTML PDF 5
10/17/22 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material HTML PDF 3
10/17/22 DEF 14A Definitive proxy statements HTML PDF 26
10/13/22 D Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. HTML PDF 5
10/12/22 8-K Current report filing HTML PDF XBRL Viewer XLS XBRL Files 2
10/03/22 PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition HTML PDF 25
08/12/22 8-K Current report filing
Related Documents
EX-99.1
HTML PDF XBRL Viewer XLS XBRL Files 4
08/11/22 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-10.1
EX-10.2
EX-10.3
EX-10.4
EX-31.1
EX-31.2
EX-32.1
HTML PDF XBRL Viewer XLS XBRL Files 60
07/07/22 8-K Current report filing
Related Documents
EX-99.1
HTML PDF XBRL Viewer XLS XBRL Files 4
RSS
  • << Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...39
  • Next >>

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2023Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap